Clinical Trial Update: Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Melanotan II as an adjunct to NB-UVB phototherapy for repigmentation in stable nonsegmental vitiligo is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo Nonsegmental

Drugs mentioned

• Melanotan II (Melanotan II)

Snippet

Sponsor: Hudson Biotech | Conditions: NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) | Phase 2 | Status: RECRUITING